Stockwatch: Bitter-sweet biotech buy-outs
This article was originally published in Scrip
Executive Summary
Speculation that the board of Amylin Pharmaceuticals recently rejected a $3.5 billion unsolicited acquisition offer from Bristol Myers Squibb (BMS) (scripintelligence.com, 29 March 2012) is both logical and fits the profile of one of the many bitter-sweet biotech buy-outs.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.